Siamak Daneshmand, MD, presented “Urine Biomarkers for the Detection of Urothelial Carcinoma​” during the International Bladder Cancer Update 2021 virtual conference in April 2021.

How to cite: Daneshmand, Siamak. “Urine Biomarkers for the Detection of Urothelial Carcinoma” April 2021. Accessed Mar 2024.

Urine Biomarkers for the Detection of Urothelial Carcinoma – Summary:

Siamak Daneshmand, MD, Associate Professor of Urology and Director of Clinical Research at the University of Southern California, discusses the ability of urinary markers to rule bladder cancer in or out and to decrease the frequency of and need for cystoscopy and cytology. He begins by stating that cystoscopy misses carcinoma in situ (CIS), upper tract tumors, and is invasive. He also notes that cytology is inconsistent, missing about 20% of high-grade disease and providing false negatives for low-grade disease. Dr. Daneshmand then considers the potential biomarkers for detection.. He reviews a study of fluorescence in situ hybridization (FISH) showing its utility in risk stratifying patients entering clinical trials who fail to respond to induction therapy, and then looks at a study of the efficacy and safety of blue light flexible cystoscopy that showed a high positive predictive value but a lack of information on patient disease. Dr. Daneshmand then summarizes the current FDA-approved urinary biomarkers and the NCCN guidelines on cystoscopy, upper tract imaging, abdominal and pelvic imaging, and urine tests before explaining that biomarkers shouldn’t be used for every patient. Dr. Daneshmand considers studies that support the use of Cxbladder, Bladder EpiCheck, Bladder CARE, and Decipher Bladder. He concludes with reviews of a study on precystectomy epithelial tumor marker response to neoadjuvant chemotherapy  and of a study on the clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma.

About the International Bladder Cancer Update 2021 virtual conference:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.